CEL-SCI Corp (CVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CEL-SCI Corp (CVM) has a cash flow conversion efficiency ratio of -0.361x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.02 Million) by net assets ($11.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CEL-SCI Corp - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how CEL-SCI Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CVM total debt and obligations for a breakdown of total debt and financial obligations.
CEL-SCI Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CEL-SCI Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voyageur Pharmaceuticals Ltd
V:VM
|
-0.295x |
|
Minrex Resources Ltd
AU:MRR
|
-0.060x |
|
Avicanna Inc
TO:AVCN
|
-0.017x |
|
Greencore Group
LSE:GNC
|
0.221x |
|
Eurobattery Minerals AB
F:EBM
|
-0.023x |
|
Orissa Bengal Carrier Limited
NSE:OBCL
|
0.014x |
|
MODERN COMMERCE SA ZY-10
F:8F4
|
0.126x |
|
TR Property Investment Trust plc
LSE:TRY
|
0.028x |
Annual Cash Flow Conversion Efficiency for CEL-SCI Corp (1989–2025)
The table below shows the annual cash flow conversion efficiency of CEL-SCI Corp from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see CVM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $15.96 Million | $-17.12 Billion | -1072.861x | -73284.95% |
| 2024-09-30 | $12.87 Million | $-18.81 Million | -1.462x | +15.44% |
| 2023-09-30 | $13.21 Million | $-22.85 Million | -1.729x | -204.86% |
| 2022-09-30 | $32.16 Million | $-18.24 Million | -0.567x | -70.66% |
| 2021-09-30 | $56.53 Million | $-18.79 Million | -0.332x | +57.09% |
| 2020-09-30 | $19.73 Million | $-15.28 Million | -0.774x | +75.64% |
| 2019-09-30 | $5.13 Million | $-16.32 Million | -3.179x | +99.98% |
| 2018-09-30 | $916.00 | $-13.39 Million | -14617.421x | -353771.50% |
| 2017-09-30 | $-3.34 Million | $-13.79 Million | 4.133x | -82.88% |
| 2016-09-30 | $-956.07K | $-23.08 Million | 24.143x | +429.82% |
| 2015-09-30 | $-5.23 Million | $-23.83 Million | 4.557x | +307.56% |
| 2014-09-30 | $10.44 Million | $-22.93 Million | -2.195x | -8.57% |
| 2013-09-30 | $6.70 Million | $-13.55 Million | -2.022x | -16.58% |
| 2012-09-30 | $7.03 Million | $-12.19 Million | -1.735x | +30.18% |
| 2011-09-30 | $9.08 Million | $-22.56 Million | -2.484x | -440.47% |
| 2010-09-30 | $27.85 Million | $-12.80 Million | -0.460x | +37.61% |
| 2009-09-30 | $8.84 Million | $-6.51 Million | -0.737x | -0.52% |
| 2008-09-30 | $10.84 Million | $-7.94 Million | -0.733x | -119.87% |
| 2007-09-30 | $14.67 Million | $-4.89 Million | -0.333x | -103.58% |
| 2006-09-30 | $-930.60K | $-8.68 Million | 9.323x | +739.38% |
| 2005-09-30 | $2.11 Million | $-3.07 Million | -1.458x | -75.65% |
| 2004-09-30 | $5.30 Million | $-4.40 Million | -0.830x | +59.94% |
| 2003-09-30 | $1.23 Million | $-2.54 Million | -2.072x | +47.99% |
| 2002-09-30 | $1.06 Million | $-4.23 Million | -3.984x | -85.67% |
| 2001-09-30 | $4.00 Million | $-8.59 Million | -2.146x | -226.12% |
| 2000-09-30 | $12.96 Million | $-8.53 Million | -0.658x | +25.84% |
| 1999-09-30 | $7.10 Million | $-6.30 Million | -0.887x | -110.55% |
| 1998-09-30 | $14.00 Million | $-5.90 Million | -0.421x | +58.57% |
| 1997-09-30 | $5.80 Million | $-5.90 Million | -1.017x | -122.64% |
| 1996-09-30 | $11.60 Million | $-5.30 Million | -0.457x | +37.34% |
| 1995-09-30 | $4.80 Million | $-3.50 Million | -0.729x | -22.14% |
| 1994-09-30 | $6.70 Million | $-4.00 Million | -0.597x | -195.79% |
| 1993-09-30 | $10.90 Million | $-2.20 Million | -0.202x | -91.74% |
| 1992-09-30 | $13.30 Million | $-1.40 Million | -0.105x | +89.47% |
| 1991-09-30 | $900.00K | $-900.00K | -1.000x | -- |
| 1990-09-30 | $0.00 | $-700.00K | x | -- |
| 1989-09-30 | $0.00 | $-500.00K | x | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more